Cohort of Patients With Ulcerative Colitis or Polyps Followed in CHU de Bordeaux Associated With a Biocollection - COLIBRI
NCT07082231 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2025-07-24
Summary
Ulcerative colitis (UC) is a chronic disease characterized by acute episodes of bloody diarrhea with varying degrees of severity. The most feared event, acute severe UC, can lead to life-threatening and systemic complications. Little is known about the determinants of severity in UC. The investigators hypothesize that distinct severity phenotypes of UC arise from intricated host-microbiota mechanisms influencing repair mechanisms. Our first and main objective is to study the natural history of UC during a one-year time period in a cohort of patients.
Conditions
- Ulcerative Colitis
- Inflammatory Bowel Disease (IBD)
- Acute Severe Ulcerative Colitis
Interventions
- OTHER
-
Blood sample
3 blood samples
- PROCEDURE
-
biopsy
3 pairs of biopsy realised during the coloscopy
Sponsors & Collaborators
-
University Hospital, Bordeaux
lead OTHER
Principal Investigators
-
Pauline RIVIERE, MD · University Hospital, Bordeaux
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-30
- Primary Completion
- 2027-09-30
- Completion
- 2027-09-30
Countries
- France
Study Locations
More Related Trials
-
Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea
NCT02229344 ·Status: COMPLETED
-
Evaluation of a Multimodal Day Hospital for the Overall Management of Patients With Chronic Inflammatory Bowel Diseases (IBD)
NCT07167186 ·Status: NOT_YET_RECRUITING
-
COLISURG : Exploratory Analysis of Sexual Function and the Impact of Biotherapies on Postoperative Morbidity.
NCT03504930 ·Status: UNKNOWN
-
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
NCT03893565 ·Status: TERMINATED ·Phase: PHASE2
-
Early Serum Infliximab Levels in Severe Ulcerative Colitis.
NCT01971814 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis
NCT07083193 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound
NCT01852760 ·Status: COMPLETED
-
IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN INFLAMMATORY BOWEL DISEASE
NCT03809728 ·Status: RECRUITING ·Phase: NA
-
Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
NCT03182166 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
NCT03178669 ·Status: COMPLETED ·Phase: PHASE2
-
Hematological Indices and Fecal Calprotectin Predict Histological Remission in Ulcerative Colitis
NCT04818788 ·Status: UNKNOWN
-
Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis
NCT02770040 ·Status: COMPLETED ·Phase: PHASE4
-
Lipid Mediators in Colonic Biopsies as Biomarkers of Disease Activity of Inflammatory Bowel Diseases
NCT01990716 ·Status: COMPLETED ·Phase: NA
-
A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis
NCT05743010 ·Status: UNKNOWN ·Phase: PHASE1
-
RCT: HDWL vs Virtual Chromoendoscopy in the Detection of Intraepithelial Neoplasia in Longstanding Colitis
NCT02822352 ·Status: COMPLETED ·Phase: NA
-
Characterization of the Intestinal Microbiota in Patients With Inflammatory Bowel Disease and/or Spondyloarthritis and Study of the Impact of an Anti-TNF Alpha Therapy
NCT03359642 ·Status: COMPLETED ·Phase: NA
-
Relationship Between Baseline Burden of Disease and TDM in Ulcerative Colitis
NCT03808506 ·Status: WITHDRAWN
-
Chronic Intestinal Pathologies Analytical Cohort at TouLouse
NCT04896684 ·Status: RECRUITING
-
Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI Biomarker Panel and Algorithm to Detect Mucosal Healing in Moderate to Severe Ulcerative Colitis Patients.
NCT04897282 ·Status: UNKNOWN
-
Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease
NCT03376230 ·Status: TERMINATED
-
Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis
NCT01408810 ·Status: COMPLETED ·Phase: PHASE4
-
Progression of Damage in Ulcerative Colitis
NCT03955328 ·Status: UNKNOWN ·Phase: NA
-
Family Members At INcreased-risk for Developing Inflammatory Bowel Disease
NCT06655415 ·Status: RECRUITING
-
Utilization of NBi in Assessing Luminal INflammaion in IBD (UNBLIND)
NCT02049775 ·Status: UNKNOWN ·Phase: NA
-
A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT04873700 ·Status: COMPLETED